甲醛组交叉反应过敏原斑贴试验的成本效益优化计算
该研究基于Mayo Clinic 1997-2022年9832例斑贴试验数据,评估甲醛组8种交叉反应过敏原的最优成本效益组合。Patch Optimization Platform分析显示,单用季铵盐15可捕获53%的甲醛组过敏接触性皮炎患者,加测甲醛1%后捕获78%,最优前5种过敏原捕获超过94%。随着检测过敏原数量增加,每增加一例诊断的增量成本最高上升44倍。
要点
- 单测季铵盐15可识别53%甲醛组过敏接触性皮炎患者
- 加测甲醛1%后识别率提升至78%,最优5种过敏原超94%
- 增加过敏原检测数量可致每诊断增量成本上升最高44倍
核心结论
- 诊断过敏性接触性皮炎时,应考虑优化的过敏原选择算法以提高成本效益。
研究设计与样本
- 回顾性分析Mayo Clinic 1997-2022年数据,共9832例接受甲醛组全部8种过敏原斑贴试验的患者,其中830例阳性。
- 使用Patch Optimization Platform确定最优单一及追加过敏原组合,成本按2022年Medicare每次斑贴试验5.19美元计算。
主要发现
- 单用季铵盐15可捕获53%的甲醛组过敏性接触性皮炎患者。
- 加测最优第二种过敏原(甲醛1%)后捕获率升至78%,最优前5种过敏原捕获超过94%。
- 随着检测过敏原数量增加,每增加一例诊断的增量成本最高上升44倍。
关键数值与推荐
- 甲醛组8种过敏原包括甲醛、季铵盐15、hexahydro-1,3,5-tris(2-hydroxyethyl)triazine、二唑烷基脲、咪唑烷基脲、甲苯磺酰胺甲醛树脂、DMDM乙内酰脲和乙烯脲三聚氰胺甲醛混合物。
- 每次斑贴试验成本为5.19美元(2022年Medicare Part B)。
临床怎么用
- 临床可参考优化算法优先选择季铵盐15和甲醛1%等关键过敏原,减少不必要的交叉反应过敏原检测以控制成本。
局限性
- 数据来自单一机构,成本按2022年Medicare Part B固定,可能限制普适性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patch testing for multiple cross-reactive allergens for allergic contact dermatitis (ACD) may not be necessary because of copositivity. OBJECTIVES: We evaluated the formaldehyde group allergens to determine the optimal, most cost-effective allergens to test. METHODS: A retrospective analysis of Mayo Clinic (1997-2022) examined the well-established copositive formaldehyde group: formaldehyde, quaternium 15, hexahydro-1,3,5-tris(2-hydroxyethyl)triazine, diazolidinyl urea, imidazolidinyl urea, toluenesulphonamide formaldehyde resin, DMDM hydantoin, and ethyleneurea melamine formaldehyde mix. Patch Optimization Platform identified which single formaldehyde-related allergen optimally captures patients with clinically relevant ACD. Next, Patch Optimization Platform determined the optimal additional 1, 2, 3, etc. allergens. Cost per patch test was $5.19 (Medicare 2022). RESULTS: A total of 9832 patients were tested for all listed allergens, with 830 having positive patch test results. Patch Optimization Platform determined that quaternium 15 alone captures 53% of patients with ACD to the formaldehyde group; adding the optimal second allergen (formaldehyde 1%) captures 78%; the optimal 5 top allergens capture >94% of patients. The incremental cost per additional diagnosis increased up to 44-fold as the number of allergens tested increased. LIMITATIONS: Data are from a single institution, and the cost per test was fixed according to Medicare Part B in 2022. CONCLUSIONS: For diagnosing ACD, we recommend considering an optimized allergen selection algorithm.
引用
- McKenzie NC, Buras MR, Yiannias JA, et al. Cost-effectiveness of patch testing allergens within the same group: A computational approach to optimize formaldehyde-related allergen selection. J Am Acad Dermatol. 2024. PMID: 38972480. doi:10.1016/j.jaad.2024.06.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。